HVTN 313: A Phase 1 research study to test an experimental vaccine against HIV
Brief description of study
The primary hypotheses are that the vaccine regimens will be safe and well tolerated and the prime-boost vaccine regimens that include Ad4-Env145NFL and Trimer 4571 as heterologous boosts will contribute to the development of B-cell and antibody (Ab) responses directed to the cross-conserved CD4 binding site (CD4bs) and gp120/gp41 fusion peptide interface or other regions with the potential to elicit heterologous neutralization.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Negative HIV
-
Age: - 55 Years
-
Gender: All
Inclusion Criteria:
- 18-55
- Low likelihood of acquiring HIV
- Negative HIV
Exclusion Criteria:
- Breastfeeding or Pregnant
- Clinically significant medical condition
Updated on
13 Mar 2024.
Study ID: 855412
Pre-Screener
